Moneycontrol PRO

you are here: HomeNewsBusinessEarningsLupin to focus on new product infusion in FY13

SHOW NAMES

Trending Topics

business

Lupin to focus on new product infusion in FY13

Higher tax expenses led to a decline in consolidated net profit of pharma company, Lupin in the fourth quarter of FY12. The company posted a decline of 31% year-on-year to Rs 156 crore. However, net sales were up 25% between January-March at Rs 1,883.2 crore.

first published: May 10, 2012 05:48 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347